This site is intended for healthcare professionals
Blue test tubes arranged in a line, disappearing into the background
  • Home
  • /
  • News
  • /
  • 2025
  • /
  • 4
  • /
  • NICE (UK) terminated appraisal for Onivyde (pegyla...
News

NICE (UK) terminated appraisal for Onivyde (pegylated liposomal irinotecan) in combination for untreated metastatic pancreatic cancer - Servier

Read time: 1 mins
Published:4th Apr 2025
"

NICE (UK) is unable to make a recommendation about the use in the NHS of pegylated liposomal irinotecan plus oxaliplatin, 5-fluorouracil and leucovorin for untreated metastatic pancreatic cancer in adults. This is because Servier has confirmed that it does not intend to make an evidence submission for the appraisal. Servier considers that there is unlikely to be enough evidence that the technology is a cost-effective use of NHS resources for this population.

Condition: Pancreatic Cancer
Type: drug
How do you prefer to access medical updates and information?

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.